Organization
University of Copenhagen
9 clinical trials
5 abstracts
Clinical trial
The Effect of Glucose-dependent Insulinotropic Polypeptide (GIP), Glucagon-like Peptide-1 (GLP-1) and Glucagon-like Peptide-2 (GLP-2) in Individuals With Genetically Altered Receptor FunctionStatus: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Effects of Changing Intestinal Transit Time on Gut Microbial Composition and Metabolism During a Dietary Intervention With Low and High Fiber.Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Effect of Cricket Enriched Porridge and Nutrition Education on Stunting, Gut Health and Breastmilk Intake of Infants and Young Children in Western KenyaStatus: Recruiting, Estimated PCD: 2024-01-16
Clinical trial
The Effect of Medical Cannabidiol on Lean Body Mass in Patients Receiving Oxaliplatin or Paclitaxel Based ChemotherapyStatus: Completed, Estimated PCD: 2021-08-30
Clinical trial
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development in Healthy and Insulin Resistant SubjectsStatus: Completed, Estimated PCD: 2020-01-01
Clinical trial
Repurposing Colchicine to Improve Vascular Function in HypertensionStatus: Completed, Estimated PCD: 2022-12-01
Clinical trial
Plasma and Exosome Proteomic Changes Associated With Augmented Erythropoiesis and Muscle Contractions.Status: Active (not recruiting), Estimated PCD: 2021-05-17
Clinical trial
Mechanistic Target of Rapamycin (mTOR) as Mediator of Exercise-induced Insulin Sensitivity StudyStatus: Recruiting, Estimated PCD: 2029-06-01
Clinical trial
Tracing Changed Production of Red Blood CellsStatus: Completed, Estimated PCD: 2022-12-16
Abstract
Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer.Org: Vejle Hospital, Aarhus University Hospital, Hillerød Hospital, Herlev Hospital, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark,
Abstract
A MACHINE LEARNING MODEL FOR IDENTIFYING IMPORTANT CLINICAL VARIABLES AND PREDICTING ONE-YEAR TREATMENT RETENTION IN PATIENTS WITH RHEUMATOID ARTHRITIS PERFORMING AN INFLIXIMAB BIOSIMILAR-TO-BIOSIMILAR SWITCHOrg: ZiteLab ApS, University Hospital of Copenhagen Rigshospitalet, DANBIO, Dept of Rheumatology, University hospital, Hvidovre, Copenhagen Center for Arthritis Research (COPECARE), Centre for Rheumatology and Spine Diseases, Center for Rheumatology and Spine Diseases,
Abstract
ANTI-IL-6 RECEPTOR INTERVENTION STRONGLY ATTENUATES MACROPHAGE AND T-CELL ACTIVITYOrg: Nordic Bioscience, University of Copenhagen,
Abstract
ANATOMICAL DISTRIBUTION OF MRI LESIONS IN axSpA AND DIFFERENCES BETWEEN PATIENTS WITH AND WITHOUT PERIPHERAL INVOLVEMENT: RESULTS FROM THE ASAS CLASSIFICATION COHORTOrg: University College London, Centre for Rheumatology, Division of Medicine, London, United Kingdom, Hacettepe University Cancer Institute, University of Alberta, Ruhr-University Bochum, Herne, Tel-Aviv University Medical School,
Abstract
BENEFIT–RISK ANALYSIS OF UPADACITINIB VERSUS ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND HIGHER OR LOWER RISK OF CARDIOVASCULAR DISEASEOrg: AbbVie Inc., North Chicago, IL, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, Rheumatism Foundation Hospital, Heinola, National Public Health Institute, Helsinki, Finland, Centre for Immunology and Cancer Research, University of Queensland, Brisbane, Australia, Emeritus Research Melbourne, Monash University School of Public Health and Preventive Medicine, Organización Medica de Investigación,